Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 3, 1998, Pages 161-170

  Tanaka, E ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; DEBRISOQUINE; ERYTHROMYCIN; LIDOCAINE; LIVER ENZYME; MEPHENYTOIN; NIFEDIPINE; PHENYTOIN; SPARTEINE;

DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; LIVER DISEASE; LIVER FUNCTION TEST; LIVER MICROSOME; REVIEW;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; LIVER DISEASES; LIVER FUNCTION TESTS;

EID: 0031755484     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00135.x     Document Type: Review

References (117)

1. Clark DWJ. (1985) Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs, 29, 342-375.
2. Kalow W. (1987) Genetic variation in the human hepatic cytochrome P-450 system. European Journal of Clinical Pharmacology, 51, 633-641.
3. Kimberling WJ, Goldgar DE, Penno MB, Vesell ES. (1987) Pharmacogenetic application of methods from population genetics. Clinical Pharmacology and Therapeutics, 41, 3-10.
4. Kupfer A, Zeugin T, Preisig R. Pharmacogenetics aspects of biological variability. Journal of Gastroenterology and Hepatology, 3, 623-633.
5. Relling MV. (1989) Polymorphic drug metabolism. Clinical Pharmacy, 8, 852-863.
6. Jacqz-Aigrain E. (1989) Genetic polymorphisms of drug metabolism. Developmental Pharmacology and Therapeutics, 13, 78-87.
7. Lou YC. (1990) Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metabolism Reviews, 22, 451-475.
8. Meyer UA, Zanger UM, Grant D, Blum M. (1990) Genetic polymorphisms of drug metabolism. Advances in Drug Research, 19, 197-241.
9. Meyer UA. (1990) Molecular genetics and the future of pharmacogenetics. Pharmacology and Therapeutics, 46, 349-355.
10. Loft S, Poulsen HE. (1990) Prediction of xenobiotic metabolism by non-invasive methods. Pharmacology and Toxicology, 67, 101-108.
11. Watkins PB. (1990) Role of cytochrome P450 in drug metabolism and hepatotoxicity. Seminars in Liver Disease, 10, 235-250.
12. Wood AJJ, Zhou HH. (1991) Ethnic differences in drug disposition and responsiveness. Clinical Pharmacokinetics, 20, 350-373.
13. Cholerton S, Daly AK, Idle JR. (1992) The role of individual human cytochrome P450 in drug metabolism and clinical response. Trends in Pharmacological Sciences, 13, 434-439.
14. Soucek P, Gut I. (1992) Cytochrome P-450 in rat: structures, functions, properties and relevant human forms. Xenobiotica, 22, 83-103.
15. Wrighton SA, Stevens JC. (1992) The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1-21.
16. Gonzalez FJ, Idle JR. (1994) Pharmacogenetic phenotyping and genotyping. Clinical Pharmacokinetics, 26, 59-70.
17. Watokins PB. (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171-184.
18. Bertolsson L. (1995) Geographical/interratical differences in polymorphic drug oxidation. Clinical Pharmacokinetics, 29, 192-209.
19. Jalan R, Hayes PC. (1995) Review article: quantitative tests of liver function. Alimentary Pharmacology and Therapeutics, 9, 263-270.
20. Meyer UA. (1996) Overview of enzymes of drug metabolism. Journal of Pharmacokinetics and Biopharmaceutics, 24, 449-459.
21. Wrighton SA, Branden MV, Ring BJ. (1996) The human drug metabolizing cytochrome P450. Journal of Pharmacokinitics and Biopharmaceutics, 24, 461-473.
22. Wilkinson GR. (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of Pharmacokinetics and Biopharmaceutics, 24, 475-490.
23. Eichelbaum M, Evert. (1996) Influence of pharmacogenetics on drug disposition and response. Clinical and Experimental Pharmacology and Physiology, 23, 983-985.
24. Wilkinson GR. (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of Pharmacokinetics and Biopharmaceutics, 24, 475-490.
25. Echelbaum M, Evert B. (1996) Influence of pharmacogenetics on drug disposition and response. Clinical and Experimental Pharmacology and Physiology, 23, 983-985.
26. Linder MW, Prough RA, Valdes R. (1997) Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clinical Chemistry, 43, 254-266.
27. Nakamura K, Goto F, Ray WA, et al. (1985) Interethnic differences in genetic polymorphism of debrisoquin and mepheytoin hydroxylation between Japanese and Caucasian population. Clinical Pharmacology and Therapeutics, 38, 402-408.
28. Wilkinson GR, Guengerich FP, Branch RA. (1989) Genetic polymorphism of S-mepheytoin hydroxylation. Pharmacology and Therapeutics, 43, 53-76.
29. Bertilsson L, Lou YQ, Du YL, et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mepheytoin. Clinical Pharmacology and Therapeutics, 51, 388-397.
30. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden. (1993) Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mepheytoin hydroxylation. Archives of Biochemistry and Biophysics, 306, 240-245.
31. Mehgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet, 2, 584-586.
32. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16, 183-187.
33. Brøsen K, Gram LF. (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology, 36, 537-547.
34. Meyer UA, Skoda RC, Zanger UM. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: Molecular mechanisms. Pharmacology and Therapeutics, 46, 297-308.
35. Eichelbaum M, Gross AS. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacology and Therapeutics, 46, 377-394.
36. Lennard MS. (1990) Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacology and Toxicology, 67, 273-283.
37. Gonzalez FK, Meyer UA. (1991) Molecular genetics of the debrisoquine/sparteine metabolism. Clinical Pharmacology and Therapeutics, 50, 233-238.
38. Kupfer A, Schmidt B, Preisig R, Pfaff G. (1984) Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet, 2, 517-518.
39. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. (1993) CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3, 197-204.
40. Marinac JS, Foxworth JW, Willsie SK. (1995) Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black american adult subjects. Therapeutic Drug Monitoring, 17, 120-124.
41. Wilkinson GR, Schenker S. (1975) Drug disposition and liver disease. Drug Metabolism Reviews, 4, 139-175.
42. Bass NM, Williams RL. (1988) Guide to drug dosage in hepatic disease. Clinical Pharmacokinetics, 15, 396-420.
43. Howden CW, Birnie GG, Brodie MJ. (1989) Drug metabolism in liver disease. Pharmacology and Therapeutics, 40, 439-474.
44. Barstow L, Small RE. (1990) Liver function assessment by drug metabolism. Pharmacotherapy, 10, 280-288.
45. Tygstrup N. (1990) Assessment of liver function: principles and practice. Journal of Gastroenterology and Hepatology, 5, 468-482.
46. McLean AJ, Morgan DJ. (1991) Clinical pharmacokinetics in patients with liver disease. Clinical Pharmacokinetics, 21, 42-69.
47. Morgan DJ, McLeen AJ. (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. Clinical Pharmacokinetics, 29, 370-391.
48. Renner EL. (1995) Liver function test. Gastroenterology, 9, 661-677.
49. Huet PM, Villeneuve JP, Fenyves D. (1997) Drug elimination in chronic liver disease. Journal of Hepatology, 26 (Suppl. 2), 63-72.
50. Tanaka E, Breimmer DD. (1997) In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. Journal of Clinical Pharmacy and Therapeutics, 22, 237-249.
51. Paintaud G, Bechtel Y, Brientini M-P, Miguet J-P, Bechtel PR. (1996) Effects of liver diseases on drug metabolism. Therapy, 51, 384-389.
52. Sonne J. (1996) Drug metabolism in liver disease: implications for therapeutic drug monitoring. Therapeutic Drug Monitoring, 18, 397-401.
53. Horsmans Y. (1997) Major cytochrome P-450 families: implications in health and liver disease. Acta Gastroenterologica Belgica, 60, 2-10.
54. Lown KL, Kolars J, Turgeon K, Morion R, Wrighton SA, Watokins PB. (1442) The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clinical Pharmacology and Therapeutics, 51, 224-238.
55. George J, Murray M, Byth K, Farrell GC. (1995) Differential alteration of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology, 21, 120-128.
56. George J, Liddle C, Murray M, Byth K, Farrell GC. (1443) Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochemical Pharmacology, 49, 873-881.
57. Shimada T, Yamazaki H, Mimura M, Inui Y, Guemgerich FP. (1444) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
58. Campbell ME, Grant DM, Inaba T, Kalow W. (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P450 in human liver microsomes. Drug Metabolism and Disposition, 15, 237-244.
59. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. (1989) Human cytochrome P-450 pa (P450 1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic aryl amines. Biochemistry, 86, 7696-7700.
60. Fuhr U, Rost KL. (1994) Simple and reliable GYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics, 4, 109-116.
61. Tanaka E, Ishikawa A, Yamamoto Y, et al. (1992) A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. International Journal of Clinical Pharmacology Therapy and Toxicology, 30, 336-341.
62. Tanaka E, Yamamoto Y, Ishikawa A, Osada A, Tsuji K, Fukao K. (1994) Effect of cigarette on caffeine and trimethadione N-demethylation catalyzed by different cytochrome P450 isozymes in patients with cirrhosis. International Hepatology Communication, 2, 341-346.
63. Lelo A, Miners JO, Robson RA, Birkett DJ. (1486) Quantitative assessment of caffeine partial clearances in man. British Journal of Clinical Pharmacology, 22, 183-186.
64. Holstege A, Staiger M, Haag K, Gerok W. (1989) Correlation of caffeine elimination and Child's classification in liver cirrhosis. Klinische Wochenschrift, 67, 6-15.
65. Scott NR, Stambuk D, Chakraborty J, Marks V, Morgan MY. (1989) The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. British Journal of Clinical Pharmacology, 27, 205-213.
66. Lewis FW, Rector WG. (1992) Caffeine clearance in cirrhosis: The value of simplified determinations of liver metabolic capacity. Journal of Hepatology, 14, 157-162.
67. Denaro CP, Wilson M, Jacob P, Benowitz, (1996) Variation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clinical Pharmacology and Therapeutics, 59, 284-296.
68. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. (1996) Caffeine urinary metabolite ratios as makers of enzyme activity: a theoretical assessment. Pharmacogenetics, 6, 121-149.
69. Fuhr U, Rost KL, Engelhardt R, et al. (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics, 6, 159-176.
70. Denaro CP, Wilson M, Jacob P, Benowitz NL. (1996) The effect of liver disease on urine caffeine metabolite ratios. Clinical Pharmacology and Therapeutics, 59, 624-635.
71. Parker AC, Preston T, Heaf D, Kitteringham NR, Choonara I. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. British Journal of Clinical Pharmacology, 38, 573-576.
72. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. (1996) The caffeine breath test dose not identify patients susceptible to tacrine hepatotoxicity. Hepatology, 23, 1429-1435.
73. Sotaniemi EA, Rautio A, Backstrom M, Arvera P, Pelukonen O. (1995) CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. British Journal of Clinical Pharmacology, 39, 71-76.
74. Raunio H, Syngelma T, Pasanen M, et al. (1988) Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat and mouse. Biochemical Pharmacology, 37, 3889-3895.
75. Pelukonen O, Raunio H, Rautio A, Maenpaa J, Lang MA. (1993) Coumarin 7-hydroxylase: characteristics and regulation in mouse and man. Journal of the Irish Colleges of Physicians and Surgeons, 22 (Suppl. 1), 24-28.
76. Kraul H, Truckenbrodt J, Huster A, Topfer R, Hoffman A. (1991) Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity. European Journal of Clinical Pharmacology, 41, 475-480.
77. Horsmans Y, Kaniynda, JM, Desager JP. (1996) Relationship between mephenytoin, phenytoin and tolubtamide hydroxylations in healthy African subjects. Pharmacology and Toxicology, 78, 86-88.
78. Koop DR. (1992) Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal, 6, 724-730.
79. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP. (1990) Hydroxilation of chlorzoxazone as a specific probe for human liver cytochrome P4502E1. Chemical Research Toxicology, 3, 566-573.
80. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FL. (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5, 143-150.
81. Yamazaki H, Guo Z, Guengerich P. (1995) Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metabolism and Disposition, 23, 438-440.
82. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. (1994) Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochemical Pharmacology, 47, 1503-1508.
83. Hayashi S, Watanabe J, Kawajiri K. (1991) Genetic polymorphisms on the 5′-flanking region change transcriptional regulation of the human cytochrome P4502E1 gene. Journal of Biochemistry, 110, 559-565.
84. Persson I, Johansson, Bergling H, et al. (1993) Genetic polymorphism of cytochrome P4502E1 in Swedish population. Relationship to incidence of lung cancer. FEBS Letters, 319, 207-211.
85. Kim RB, Yamazaki H, Chiba K, et al. (1996) In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. The Journal of Pharmacology and Experimental Therapeutics, 279, 4-11.
86. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watokins PB. (1992) Identification of rifampin-inducible P450III A4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigation, 90, 1871-1878.
87. Wilkinson GR. (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of Pharmacokinetics and Biopharmaceutics, 24, 475-490.
88. Kleinbloesem CH, van Harten J, Wilson JP, Danhof M, van Brummelen, Breimer DD. (1986) Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clinical Pharmacology and Therapeutics, 40, 21-28.
89. Watkins PB, Murray SA, Winkelman LC, Heuman DM, Wrighton SA, Guzerian PS. (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P450. Journal of Clinical Investigation, 83, 688-697.
90. Lown K, Kolarus J, Turgeon DK, Merion R, Wrighton SA, Watokins PB. (1992) The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clinical Pharmacology and Therapeutics, 51, 229-238.
91. Watkins PB. (1996) Erythromycin breath test and clinical transplantation. Therapeutic Drug Monitoring, 18, 368-371.
92. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA4. Clinical Pharmacology and Therapeutics, 46, 521-527.
93. Oellerich M, Raude E, Burdelski M, et al. (1987) Monoethylglycinexylidide formation kinetics (A novel approach to assessment of liver function). Journal of Clinical Chemistry and Clinical Biochemistry, 25, 845-853.
94. Oellerich M, Burdelski M, Beyrau R, et al. (1989) Lidocaine metabolite formation as a early post-transplant liver function. Hepatology, 10, 625 (Abstract).
95. Oellerich M, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann H. (1990) Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Therapeutic Drug Monitoring, 12, 219-226.
96. Huang YS, Lee SD, Deng JF, et al. (1993) Measuring lidocaine metabolite monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. Journal of Hepatology, 19, 140-147.
97. Shimanuki K, Suzuki W, Sakurabayashi I, et al. (1993) Evaluation of lidocaine metabolite (monoethylglycinexylidide) as a liver function test. Japanese Journal of Gastroenterology, 90, 33-40 (Abstract).
98. Oda Y, Kariya N, Nakamoto T, Nishi S, Asada A, Fujimori, M. (1995) The monoethylglycinexylidide test is more useful for evaluating liver function than indocyanine green test: case of patients a patient with remarkable decreased indocyanine green half-life. Therapeutic Drug Monitoring, 17, 207-210.
99. Shiffman ML, Luketic VA, Sanyal AJ, Thompson EB. (1996) Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease. Therapeutic Drug Monitoring, 18, 372-377.
100. Oellerich M, Burdelski M, Ringe B, et al. (1989) Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet, 1, 640-642.
101. Lamesch P, Ringe B, Oellerich M, et al. (1990) Assessment of liver function in the early postoperative period after liver transplantation with ICC, MEGX, and GAL tests. Transplantation Proceedings, 22, 1539-1541.
102. Rossi SJ, Schroeder TJ, Vine WH, et al. (1992) Monoethylglycinexylide formation in assessing pediatric donor liver function. Therapeutic Drug Monitoring, 14, 452-456.
103. Oellerich M, Schutz E, Polzien FI, et al. (1994) Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors. Therapeutic Drug Monitoring, 16, 225-231.
104. Burdelski M, Schutz E, Nolte-Buchholtz S, Armstrong VW, Oellerich M. (1996) Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates. Therapeutic Drug Monitoring, 18, 378-382.
105. Potter JM, Hickman PE, Henderson A, Balderson GA, Lynch SV, Strong RW. (1996) The use of the lidocaine-monoethylglycinexylidide test in the liver transplant recipient. Therapeutic Drug Monitoring, 18, 383-387.
106. Shiffman M, Luketic VA, Sanyal AJ, Balderson GA, Lynch SV, Strong RW. (1994) Hepatic lidocaine metabolism and liver histology in patients with chronic-hepatitis and cirrhosis. Hepatology, 19, 933-940.
107. Tsuneoka Y, Fukushima K, Matsuo Y, Ichikawa Y, Watanabe Y. (1996) Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sciences, 59, 1711-1715.
108. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. European Journal of Clinical Pharmacology, 39, 533-537.
109. Larrey D, Babany G, Tinel M, et al. (1989) Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients. British Journal of Clinical Pharmacology, 28, 297-304.
110. Figg WD, Dukes GE, Lesesne HR, et al. (1995) Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy, 15, 693-700.
111. Lanthier PL, Reshef R, Shah RR, Oates NS, Smith RL, Morgan MY. (1984) Oxidation phonotyping in alcoholics with liver disease of varying severity. Alcoholism, Clinical and Experimental Research, 8, 435-441.
112. Joanne C, Paintaud G, Bresson-Hadni S, et al. (1994) Is debrisoquine hydroxylation modified during acute viral hepatitis? Fundamental and Clinical Pharmacology, 8, 76-79.
113. Barry M, Feely J. (1990) Enzyme induction and inhibition. Pharmacology and Therapeutics, 48, 71-94.
114. Breimer DD. (1983) Interindividual variations in drug disposition. Clinical Pharmacokinetics, 8, 371-377.
115. Vesell ES. (1984) Complex effects of diet on drug disposition. Clinical Pharmacology and Therapeutics, 36, 285-296.
116. Pelkonen O, Breimer DD. (1994) Role of environmental factors in the pharmacokinetics of drugs: considerations with respect to animal models, P-450 enzymes, and probe drugs. In Handbook of Experimental Pharmacology. eds Welling PG, Balant LP. pp. 289-332. Springer-Verlag, Berlin.
117. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. (1997) Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes. Clinical Pharmacology and Therapeutics, 62, 365-376.